BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1472633)

  • 1. Autoantibodies to c-myc protein: elevated levels in patients with African Burkitt's lymphoma and normal Ghanians.
    LaFond RE; Eaton RB; Watt RA; Villee CA; Actor JK; Schur PH
    Autoimmunity; 1992; 13(3):215-24. PubMed ID: 1472633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.
    Madisen L; Groudine M
    Genes Dev; 1994 Sep; 8(18):2212-26. PubMed ID: 7958890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies in Burkitt's lymphoma patients from the Ugandan prospective study.
    Mori H; Lenoir GM; Franklin RM
    Trop Med Parasitol; 1986 Mar; 37(1):9-14. PubMed ID: 3518027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus and Burkitt's lymphoma.
    Magrath I; Jain V; Bhatia K
    Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
    Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
    Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-myc hypermutation in Burkitt's lymphoma.
    Johnston JM; Carroll WL
    Leuk Lymphoma; 1992 Dec; 8(6):431-9. PubMed ID: 1297477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular genetic features of sporadic Burkitt's lymphoma in children].
    Yang WP; Huang H; Gong LP; Wu Y; Xu HY; Zou Y; Lü BB; Zhong HS; Deng QQ; Xiao Q; Zeng ST; Zhu CD
    Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):819-24. PubMed ID: 21215097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
    Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
    Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
    Bemark M; Neuberger MS
    Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.
    Rabbitts TH; Forster A; Hamlyn P; Baer R
    Nature; 1984 Jun 14-20; 309(5969):592-7. PubMed ID: 6547209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular biology of Burkitt's lymphoma.
    Hecht JL; Aster JC
    J Clin Oncol; 2000 Nov; 18(21):3707-21. PubMed ID: 11054444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translocations among antibody genes in human cancer.
    Leder P
    IARC Sci Publ; 1985; (60):341-57. PubMed ID: 4065947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential c-myc protein expression in Burkitt's lymphomas and EBV-transformed lymphoblastoid lines.
    Wennborg AD; Altiok E; Moore JP; Ernberg I; Klein G
    Eur J Cancer; 1991; 27(12):1643-5. PubMed ID: 1782076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology of the lymphomas: cytogenetics, molecular biology, and virology.
    Ambinder RF; Griffin CA
    Curr Opin Oncol; 1991 Oct; 3(5):806-12. PubMed ID: 1661167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
    Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
    Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.
    Yan Y; Park SS; Janz S; Eckhardt LA
    Genes Chromosomes Cancer; 2007 Oct; 46(10):950-9. PubMed ID: 17639584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
    Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
    Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-MYC impairs immunogenicity of human B cells.
    Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
    Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies in three populations of Burkitt's lymphoma patients.
    Vainio E; Lenoir GM; Franklin RM
    Clin Exp Immunol; 1983 Nov; 54(2):387-96. PubMed ID: 6317239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus (EBV) genomes and c-myc oncogene in oral Burkitt's lymphomas.
    Syrjänen S; Kallio P; Sainio P; Fuju C; Syrjänen K
    Scand J Dent Res; 1992 Jun; 100(3):176-80. PubMed ID: 1321486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.